SCHEMBL6069223

SCHEMBL6069223

O=CC(Cl)=CCl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6069219 1.00
SCHEMBL6947208 0.69
SCHEMBL11168686 0.69
SCHEMBL6947211 0.69
SCHEMBL9539435 0.69
SCHEMBL11168687 0.69
SCHEMBL15117379 0.69
SCHEMBL23093029 0.67
SCHEMBL10801330 0.67
SCHEMBL10801326 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110128421-B Simple preparation method of 5-halogenated-7-azaindole 新发药业有限公司 2020-08-11 CN claimed
CN-110128421-B Simple preparation method of 5-halogenated-7-azaindole 新发药业有限公司 2020-08-11 CN disclosed
CN-103443093-B Novel compounds as histamine H3 receptor ligands SUVEN LIFE SCIENCES LTD 2015-02-25 CN disclosed
US-7060715-B2 Substituted pyridines as selective cyclooxygenase-2 inhibitors MERCK FROSST CANADA LTD. (CA) 2006-06-13 US disclosed
US-20050009875-A1 Substituted pyridines as selective cyclooxygenase-2 inhibitors MERCK CANADA INC. (CA) 2005-01-13 US disclosed
US-6812346-B2 ANTIINFLAMMATORY AGENTS; ANTIPYRETICS; ANALGESICS MERCK FROSST CANADA AND CO. (CA) 2004-11-02 US disclosed
EP-0975596-B1 PROCESS FOR MAKING 2-ARYL-3-ARYL-5-HALO PYRIDINES USEFUL AS COX-2 INHIBITORS MERCK & CO INC (US) 2004-06-30 EP disclosed
US-20040029921-A1 Substituted pyridines as selective cyclooxygenase-2 inhibitors MERCK FROSST CANADA & CO. 2004-02-12 US disclosed
US-6596736-B2 Well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non- toxic therapeutically effective amount of a compound of Formula I. pain, dysmenorrhea, myositis, MERCK & CO., INC. 2003-07-22 US disclosed
US-20030065011-A1 Substituted pyridines as selective cyclooxygenase-2 inhibitors MERCK FROSST CANADA & CO. 2003-04-03 US disclosed
WO-1999015503-A2 PROCESS FOR MAKING DIARYL PYRIDINES USEFUL AS COX-2 INHIBITORS MERCK & CO., INC. (US) 1999-04-01 WO disclosed
WO-1998047871-A1 PROCESS FOR MAKING 2-ARYL-3-ARYL-5-HALO PYRIDINES USEFUL AS COX-2 INHIBITORS MERCK & CO., INC. (US) 1998-10-29 WO disclosed
EP-0352959-B1 RESOLUTION PROCESS FOR RACEMIC SPIRO-HYDANTOINS PFIZER INC. (US) 1993-09-01 EP disclosed
US-5206367-A Preparation of optically active spiro-hydantoins PFIZER INC. (US) 1993-04-27 US disclosed
US-5006657-A Intermediates in a resolution process for racemic spiro hydantoins PFIZER INC. (US) 1991-04-09 US disclosed
US-4952694-A Novel resolution process for racemic spiro-hydantoins PFIZER INC. (US) 1990-08-28 US disclosed
EP-0352959-A1 Resolution process for racemic spiro-hydantoins PFIZER INC. (US) 1990-01-31 EP disclosed
EP-0168732-B1 PROCESS FOR THE PREPARATION OF HALOGENATED AROYLACETIC ACID ESTERS BAYER AG (DE) 1988-07-27 EP disclosed
EP-0168732-A2 Process for the preparation of halogenated aroylacetic acid esters BAYER AG (DE) 1986-01-22 EP disclosed
US-4017484-A Cationic dyestuffs BAYER AKTIENGESELLSCHAFT (DT) 1977-04-12 US disclosed